Application of small interfering RNAs and drug combination for pancreatic cancer therapy.

IF 4.7 4区医学 Q1 PHARMACOLOGY & PHARMACY

Journal of Drug Targeting Pub Date : 2026-11-01 Epub Date: 2026-06-01 DOI:10.1080/1061186X.2026.2663993

Chaoyang Zeng, Shu-Zhen Chen

引用次数: 0

Abstract

In recent years, pancreatic cancer has become one of the major causes of death among cancers. It has been confirmed that changes in the expression of various genes are important factors associated with the occurrence and development of pancreatic cancer. Small interfering RNAs (siRNAs) are 21-25nt ribonucleotides that target specific DNA sequences and reduce their expression levels. An siRNA delivery system is required as a common and effective method for cancer treatment. Silencing the expression of critical genes (K-Ras, GJB4, SIX4, RARγ, etc) via siRNAs can effectively block the development of pancreatic cancer or even reverse its progression. Moreover, siRNAs can improve the efficacy of clinical chemotherapeutic drugs (doxorubicin, paclitaxel, docetaxel, gemcitabine) by reducing drug-resistance-related genes. Additionally, siRNAs are a valid approach to enhance the effectiveness of immunotherapy. This review reveals that the application of siRNAs and their combination with chemical/immunological agents may improve the treatment of pancreatic cancer.

查看原文本刊更多论文

小干扰rna及联合用药在胰腺癌治疗中的应用。

近年来，胰腺癌已成为癌症死亡的主要原因之一。已证实多种基因表达的改变是胰腺癌发生发展的重要相关因素。小干扰rna （sirna）是针对特定DNA序列并降低其表达水平的21-25nt核糖核苷酸。作为一种常见而有效的癌症治疗方法，siRNA递送系统是必需的。通过sirna沉默关键基因（K-Ras、GJB4、SIX4、RARγ等）的表达，可以有效阻断胰腺癌的发展，甚至逆转其进展。此外，sirna可以通过减少耐药相关基因来提高临床化疗药物（阿霉素、紫杉醇、多西他赛、吉西他滨）的疗效。此外，sirna是提高免疫治疗有效性的有效途径。这一综述揭示了sirna的应用及其与化学/免疫药物的联合可能会改善胰腺癌的治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Drug Targeting 医学-药学

CiteScore

9.10

自引率

0.00%

发文量

165

审稿时长

2 months

期刊介绍： Journal of Drug Targeting publishes papers and reviews on all aspects of drug delivery and targeting for molecular and macromolecular drugs including the design and characterization of carrier systems (whether colloidal, protein or polymeric) for both vitro and/or in vivo applications of these drugs. Papers are not restricted to drugs delivered by way of a carrier, but also include studies on molecular and macromolecular drugs that are designed to target specific cellular or extra-cellular molecules. As such the journal publishes results on the activity, delivery and targeting of therapeutic peptides/proteins and nucleic acids including genes/plasmid DNA, gene silencing nucleic acids (e.g. small interfering (si)RNA, antisense oligonucleotides, ribozymes, DNAzymes), as well as aptamers, mononucleotides and monoclonal antibodies and their conjugates. The diagnostic application of targeting technologies as well as targeted delivery of diagnostic and imaging agents also fall within the scope of the journal. In addition, papers are sought on self-regulating systems, systems responsive to their environment and to external stimuli and those that can produce programmed, pulsed and otherwise complex delivery patterns.